Breaking News Instant updates and real-time market news.

2023-01-25 18:02:30 CLS Celestica $13.19 / -0.03 (-0.23%) 18:02 01/25/23 01/25 18:02 01/25/23 18:02	Celestica sees Q1 adjusted EPS 41c-47c, consensus 40c Sees Q1 revenue $1.725B-$1.875B, consensus $1.72B.	26 Jan

2023-01-25 18:02:30

CLS

Celestica

$13.19 / -0.03 (-0.23%)

18:02

01/25/23

01/25

18:02

01/25/23

18:02

Celestica sees Q1 adjusted EPS 41c-47c, consensus 40c

Sees Q1 revenue $1.725B-$1.875B, consensus $1.72B.

26
Jan

OTHER BREAKING NEWS FROM THE FLY

Recommendations	Viking Therapeutics price target raised to $19 from $15 at Roth MKM » 08:23 03/29/23 03/29 08:23 03/29/23 08:23 VKTX Viking Therapeutics $15.41 / +6.28 (+68.78%) Roth MKM raised the… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Options VKTX Viking Therapeutics $15.41 / +6.28 (+68.78%) 03/28/23 Viking Therapeutics initiates Phase 1 study of novel formulation of VK2735 03/28/23 Viking Therapeutics jumps 32% to $12.06 after Phase 1 VK2735 trial results 03/28/23 Viking Therapeutics announces results from Phase 1 trial of VK2735 01/09/23 Viking Therapeutics completes enrollment in Phase 2b VOYAGE study of VK2809 VKTX Viking Therapeutics $15.41 / +6.28 (+68.78%) 08:12 Today Maxim Viking Therapeutics price target raised to $25 from $15 at Maxim 06:15 Today Raymond James Viking Therapeutics price target raised to $35 from $12 at Raymond James 03/28/23 BTIG Viking Therapeutics price target raised to $31 from $20 at BTIG 03/28/23 Oppenheimer Viking Therapeutics price target raised to $30 from $20 at Oppenheimer VKTX Viking Therapeutics $15.41 / +6.28 (+68.78%) 02/08/23 Viking Therapeutics reports Q4 EPS (26c), consensus (23c) 10/26/22 Viking Therapeutics reports Q3 EPS (21c), consensus (23c) VKTX Viking Therapeutics $15.41 / +6.28 (+68.78%) 01/02/23 Viking sued Ascletis alleging stolen trade secrets, Reuters reports VKTX Viking Therapeutics $15.41 / +6.28 (+68.78%) 03/28/23 What You Missed On Wall Street On Tuesday 03/28/23 What You Missed On Wall Street This Morning 12/21/22 Biotech Alert: Searches spiking for these stocks today 12/19/22 Trial success is rocketing this NASH stock higher and sinking these peers VKTX Viking Therapeutics $15.41 / +6.28 (+68.78%) 03/21/23 Viking Therapeutics call volume above normal and directionally bullish 03/16/23 Viking Therapeutics call volume above normal and directionally bullish 03/08/23 Viking Therapeutics call volume above normal and directionally bullish 02/17/23 Viking Therapeutics call volume above normal and directionally bullish
Earnings	Twin Vee PowerCats reports 2022 EPS (76c) vs. (19c) last year » 08:22 03/29/23 03/29 08:22 03/29/23 08:22 VEEE Twin Vee PowerCats $1.84 / +0.13 (+7.60%) Reports revenue $32M vs.… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Earnings Syndicate Events VEEE Twin Vee PowerCats $1.84 / +0.13 (+7.60%) 03/08/23 Twin Vee says initial orders of 22-foot LFG Marine boat exceeds expectations 02/17/23 Twin Vee PowerCats says LFG Marine to attend Freedom Boat Club Forum 02/15/23 Twin Vee PowerCats launches all-new boat brand LFG Marine 02/09/23 Twin Vee PowerCats to offer test rides during Miami Boat Show VEEE Twin Vee PowerCats $1.84 / +0.13 (+7.60%) 11/08/22 Twin Vee PowerCats reports Q3 EPS (13c) vs. (6c) last year 29 Sep 10:00 Today Twin Vee PowerCats - VEEE
Recommendations	Other EV startups may need to consider actions like Lucid, says Morgan Stanley » 08:22 03/29/23 03/29 08:22 03/29/23 08:22 LCID Lucid Group $7.56 / -0.58 (-7.13%) , RIVN Rivian Automotive $12.98 / -0.345 (-2.59%) , LI Li Auto $24.77 / +1.58 (+6.81%) , NIO Nio $9.21 / +0.27 (+3.02%) , XPEV XPeng $10.25 / +0.55 (+5.67%) After Lucid Group… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Events Options LCID RIVN LI NIO XPEV LCID Lucid Group $7.56 / -0.58 (-7.13%) 07:33 Today Lucid Group to cut workforce by about 18% as part of restructuring plan 03/28/23 Lucid Group down 6% to $7.64 following report of layoffs 03/27/23 Lucid recalls 2022-2023 Lucid Air vehicles for issue with electric motors 02/22/23 Lucid Group down 8% afterhours at $9.14 after Q4 results and 2023 outlook RIVN Rivian Automotive $12.98 / -0.345 (-2.59%) 02/28/23 Rivian Automotive down 6% following quarterly report 02/28/23 Rivian Automotive sees 50,000 vehicles produced in 2023 02/14/23 Greenlight buys Tenet, exits Intel in Q4 02/13/23 Soros Fund buys Horizon Therapeutics, exits BNY Mellon in Q4 LI Li Auto $24.77 / +1.58 (+6.81%) 03/01/23 Li Auto delivers 16,620 vehicles in February 02/08/23 Li Auto launches Li L7, a five-seat flagship family SUV 02/01/23 Li Auto delivers 15,141 vehicles in January 01/02/23 Fly Intel: Top five weekend stock stories NIO Nio $9.21 / +0.27 (+3.02%) 03/22/23 Nio rise 3% to $9.52 after positive CFO comments on 2023 sales 03/01/23 Nio says achieved record-breaking quarterly delivery on Q4 02/01/23 Nio delivers 8,506 vehicles in January 01/24/23 NIO trading resumes XPEV XPeng $10.25 / +0.55 (+5.67%) 03/17/23 XPeng rises 10.8% 03/17/23 XPeng announces 5,218 vehicles delivered in January 03/10/23 XPeng laiuches P7i sports sedan in China 03/01/23 XPeng delivers 6,010 Smart EVs in February LCID RIVN LI NIO XPEV LCID Lucid Group $7.56 / -0.58 (-7.13%) 03/02/23 Citi Lucid Group price target lowered to $11.50 from $12 at Citi 02/23/23 R.F. Lafferty Lucid Group price target lowered to $12 from $17 at R.F. Lafferty 02/23/23 Exane BNP Paribas Lucid Group downgraded to Neutral from Outperform at Exane BNP Paribas 02/23/23 Cantor Fitzgerald Lucid Group price target lowered to $13 from $18 at Cantor Fitzgerald RIVN Rivian Automotive $12.98 / -0.345 (-2.59%) 03/22/23 Morgan Stanley Rivian now trading just below cash value, says Morgan Stanley 03/21/23 Morgan Stanley EV price cuts 'not a fad, but a trend,' says Morgan Stanley 03/10/23 BofA Rivian Automotive resumed with Buy, reduced target at BofA 03/09/23 Mizuho Rivian Automotive price target lowered to $35 from $37 at Mizuho LI Li Auto $24.77 / +1.58 (+6.81%) 03/20/23 Morgan Stanley XPeng price target raised to $12.50 from $12 at Morgan Stanley 03/20/23 Morgan Stanley Li Auto price target raised to $30 from $23 at Morgan Stanley 03/20/23 Morgan Stanley Nio price target lowered to $12 from $16.10 at Morgan Stanley 03/03/23 HSBC Li Auto price target raised to $36 from $35 at HSBC NIO Nio $9.21 / +0.27 (+3.02%) 03/20/23 Morgan Stanley XPeng price target raised to $12.50 from $12 at Morgan Stanley 03/20/23 Morgan Stanley Li Auto price target raised to $30 from $23 at Morgan Stanley 03/20/23 Morgan Stanley Nio price target lowered to $12 from $16.10 at Morgan Stanley 03/02/23 Mizuho Nio price target lowered to $25 from $28 at Mizuho XPEV XPeng $10.25 / +0.55 (+5.67%) 03/24/23 Bernstein XPeng downgraded to Market Perform from Outperform at Bernstein 03/24/23 Bernstein XPeng downgraded to Market Perform from Outperform at Bernstein 03/20/23 Morgan Stanley XPeng price target raised to $12.50 from $12 at Morgan Stanley 03/20/23 Morgan Stanley Li Auto price target raised to $30 from $23 at Morgan Stanley LCID RIVN LI NIO XPEV LCID Lucid Group $7.56 / -0.58 (-7.13%) 02/22/23 Lucid Group reports Q4 EPS (28c), consensus (40c) 02/22/23 Notable companies reporting after market close 11/08/22 Lucid Group reports Q3 EPS (40c), consensus (31c) 11/08/22 Notable companies reporting after market close RIVN Rivian Automotive $12.98 / -0.345 (-2.59%) 02/28/23 Rivian Automotive reports Q4 adjusted EPS ($1.73), consensus ($1.94) 02/28/23 Notable companies reporting after market close 02/02/23 Amazon reports Q4 EPS 3c with Rivian loss, consensus 17c 11/09/22 Rivian Automotive reports Q3 adjusted EPS ($1.57), consensus ($1.82) LI Li Auto $24.77 / +1.58 (+6.81%) 02/27/23 Li Auto reports Q4 EPS 4c, consensus 2c 12/09/22 Li Auto sees Q4 revenue $2.32B-$2.47B, consensus $2.55B 12/09/22 Li Auto reports Q3 EPS (18c), consensus (15c) NIO Nio $9.21 / +0.27 (+3.02%) 03/01/23 Nio reports Q4 EPS (44c) 11/10/22 Nio reports Q3 adjusted EPS (30c), consensus (16c) XPEV XPeng $10.25 / +0.55 (+5.67%) 03/17/23 XPeng sees Q1 revenue down 43.7%-46.3%, consensus $882.99M 03/17/23 XPeng reports Q4 adjusted EPS (37c), consensus (36c) 11/30/22 XPeng sees Q4 revenue RMB 4.8B-RMB 5.1B 11/30/22 XPeng reports Q3 EPS (36c), consensus (36c) LCID RIVN LI NIO XPEV LCID Lucid Group $7.56 / -0.58 (-7.13%) 03/28/23 Lucid Group to eliminate 18% of workforce, Insider reports 01/30/23 Fuzzy Panda short Lucid Group, calls buyout rumor 'fake news' 01/30/23 Fuzzy Panda says sell Lucid Group on 'fake' buyout rumor 01/27/23 Lucid Group spike attributed to takeout speculation by Betaville RIVN Rivian Automotive $12.98 / -0.345 (-2.59%) 03/13/23 Amazon, Rivian in discussions to drop exclusivity part of van deal, WSJ says 03/03/23 Rivian tells staff production of 62,000 EVs possible in 2023, Bloomberg says 03/03/23 Rivian tells staff production of 62,000 EVs possible this year, Bloomberg says 02/03/23 Rivian Automotive to expand lineup with development of e-bike, Bloomberg says LI Li Auto $24.77 / +1.58 (+6.81%) 01/16/23 EVs made up 10% of all new cars sold last year, WSJ reports 12/13/22 Geely's premium brand Zeekr confidentially files for U.S. IPO, Reuters says NIO Nio $9.21 / +0.27 (+3.02%) 01/16/23 EVs made up 10% of all new cars sold last year, WSJ reports 12/26/22 Nio CEO warns of sales challenges in first half of the year, Bloomberg reports 12/13/22 Geely's premium brand Zeekr confidentially files for U.S. IPO, Reuters says XPEV XPeng $10.25 / +0.55 (+5.67%) 01/17/23 XPeng follows Tesla with price cuts in China, Reuters reports 01/16/23 EVs made up 10% of all new cars sold last year, WSJ reports LCID RIVN LI NIO XPEV LCID Lucid Group $7.56 / -0.58 (-7.13%) 03/28/23 What You Missed On Wall Street On Tuesday 02/27/23 What You Missed This Week in EVs and Clean Energy 02/23/23 What You Missed On Wall Street On Thursday 02/23/23 What You Missed On Wall Street This Morning RIVN Rivian Automotive $12.98 / -0.345 (-2.59%) 03/27/23 What You Missed This Week in EVs and Clean Energy 03/20/23 What You Missed This Week in EVs and Clean Energy 03/13/23 What You Missed On Wall Street On Monday 03/13/23 What You Missed This Week in EVs and Clean Energy LI Li Auto $24.77 / +1.58 (+6.81%) 03/20/23 What You Missed This Week in EVs and Clean Energy 02/27/23 What You Missed On Wall Street On Monday 02/27/23 What You Missed On Wall Street This Morning 02/27/23 Fly Intel: Pre-market Movers NIO Nio $9.21 / +0.27 (+3.02%) 03/26/23 Opening Day: Singapore's Ohmyhome makes Nasdaq debut 03/20/23 What You Missed This Week in EVs and Clean Energy 03/18/23 Opening Day: China's Intchains, ICZOOM make U.S. debut 03/11/23 Opening Day: Atlas Energy raises $324M in 2023's second biggest IPO XPEV XPeng $10.25 / +0.55 (+5.67%) 03/27/23 What You Missed This Week in EVs and Clean Energy 03/24/23 What You Missed On Wall Street On Friday 03/24/23 What You Missed On Wall Street This Morning 03/20/23 What You Missed This Week in EVs and Clean Energy 04/24/23 Lucid Group Inc LCID RIVN LI NIO XPEV LCID Lucid Group $7.56 / -0.58 (-7.13%) 03/21/23 Largest borrow rate increases among liquid names 02/28/23 Largest borrow rate increases among liquid names 02/27/23 Largest borrow rate increases among liquid names 02/22/23 Lucid Group options imply 13.9% move in share price post-earnings RIVN Rivian Automotive $12.98 / -0.345 (-2.59%) 03/08/23 Notable open interest changes for March 8th 03/07/23 Unusually active option classes on open March 7th 03/02/23 Rivian put buyer realizes 7% same-day gains 02/28/23 Rivian options imply 11.8% move in share price post-earnings LI Li Auto $24.77 / +1.58 (+6.81%) 02/27/23 Unusually active option classes on open February 27th 02/13/23 Li Auto call volume above normal and directionally bullish 02/13/23 Unusually active option classes on open February 13th 12/22/22 Li Auto call buyer realizes 39% same-day gains NIO Nio $9.21 / +0.27 (+3.02%) 03/13/23 NIO call volume above normal and directionally bullish 03/06/23 NIO call volume above normal and directionally bullish 03/01/23 Unusually active option classes on open March 1st 02/06/23 NIO call volume above normal and directionally bullish XPEV XPeng $10.25 / +0.55 (+5.67%) 03/21/23 Unusually active option classes on open March 21st 03/17/23 Unusually active option classes on open March 17th 03/09/23 Largest borrow rate increases among liquid names 01/30/23 XPeng call volume above normal and directionally bullish
Recommendations	Lovesac price target raised to $36 from $32 at Roth MKM » 08:21 03/29/23 03/29 08:21 03/29/23 08:21 LOVE Lovesac $27.01 / +3.055 (+12.75%) Roth MKM analyst Matt… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings On The Fly Events Options LOVE Lovesac $27.01 / +3.055 (+12.75%) 01/04/23 Lovesac director buys $847K in common stock 12/07/22 Lovesac reports Q3 SSS up 8.9% 11/03/22 Lovesac appoints John Legg as CSCO LOVE Lovesac $27.01 / +3.055 (+12.75%) 12/08/22 DA Davidson Lovesac price target lowered to $64 from $97 at DA Davidson 12/08/22 Craig-Hallum Lovesac price target lowered to $60 from $100 at Craig-Hallum 12/08/22 Canaccord Lovesac price target lowered to $50 from $55 at Canaccord 09/09/22 DA Davidson Lovesac price target lowered to $97 from $124 at DA Davidson LOVE Lovesac $27.01 / +3.055 (+12.75%) 03/28/23 Lovesac sees 2024 EPS $1.83-$2.24, consensus $2.10 03/28/23 Lovesac sees Q1 EPS (36c)-(37c), consensus (6c) 03/28/23 Lovesac reports Q4 EPS $1.74, consensus $1.72 12/07/22 Lovesac reports Q3 EPS (55c), consensus (76c) LOVE Lovesac $27.01 / +3.055 (+12.75%) 03/28/23 What You Missed On Wall Street On Tuesday 03/28/23 What You Missed On Wall Street This Morning 03/30/23 Lovesac 04/11/23 Lovesac LOVE Lovesac $27.01 / +3.055 (+12.75%) 01/06/23 Largest borrow rate increases among liquid names
Hot Stocks	Achieve Life says last subject's last visit complete for Phase 3 ORCA-3 trial » 08:20 03/29/23 03/29 08:20 03/29/23 08:20 ACHV Achieve Life Sciences $5.55 / +0.425 (+8.29%) Achieve Life Sciences… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings On The Fly ACHV Achieve Life Sciences $5.55 / +0.425 (+8.29%) 03/17/23 Achieve Life Sciences announces grant of new hire inducement award 03/08/23 Achieve Life announce last subject last visit complete in Phase 2 ORCA-V1 trial 03/03/23 Achieve Life Sciences presents Phase 3 ORCA-2 trial data 02/07/23 Achieve Life Sciences doses last subject in Phase 2 ORCA-V1 trial ACHV Achieve Life Sciences $5.55 / +0.425 (+8.29%) 11/16/22 Maxim Achieve Life Sciences price target lowered to $8 from $21 at Maxim 11/15/22 Oppenheimer Achieve Life Sciences price target lowered to $20 from $27 at Oppenheimer 04/27/22 Oppenheimer Achieve Life Sciences price target raised to $27 from $23 at Oppenheimer ACHV Achieve Life Sciences $5.55 / +0.425 (+8.29%) 03/16/23 Achieve Life Sciences reports Q4 EPS (83c), consensus (83c) 11/14/22 Achieve Life Sciences reports Q3 EPS ($1.35), consensus ($1.13) ACHV Achieve Life Sciences $5.55 / +0.425 (+8.29%) 01/12/23 Biotech Alert: Searches spiking for these stocks today
Hot Stocks	Proterra announces South Carolina Department of Education to deploy 160 TBB » 08:20 03/29/23 03/29 08:20 03/29/23 08:20 PTRA Proterra $1.50 / +0.05 (+3.45%) The South Carolina… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings On The Fly Options PTRA Proterra $1.50 / +0.05 (+3.45%) 03/24/23 Proterra congratulates LG Energy Solution on Arizona battery manufacturing 03/20/23 Proterra reaches binding letter of intent with Cowen convertible note holders 02/23/23 Proterra, Thomas Built Buses reach major milestone for electric school buses 02/13/23 Proterra appoints Julian Soell as COO, Chris Bailey as Chief Business Officer PTRA Proterra $1.50 / +0.05 (+3.45%) 03/17/23 DA Davidson Proterra price target lowered to $5 from $10 at DA Davidson 03/16/23 BTIG Proterra price target lowered to $6 from $7 at BTIG 10/17/22 BTIG Proterra initiated with a Buy at BTIG 09/28/22 Truist Truist starts Proterra at Buy, positive on commercial EV battery niche PTRA Proterra $1.50 / +0.05 (+3.45%) 03/15/23 Proterra sees FY23 revenue $450M-$500M, consensus $533.8M 03/15/23 Proterra reports Q4 EPS (50c), consensus (25c) PTRA Proterra $1.50 / +0.05 (+3.45%) 03/16/23 What You Missed On Wall Street On Thursday 03/16/23 What You Missed On Wall Street This Morning 10/17/22 What You Missed This Week in EVs and Clean Energy PTRA Proterra $1.50 / +0.05 (+3.45%) 03/08/23 Proterra options imply 8.3% move in share price post-earnings 03/03/23 Unusually active option classes on open March 3rd
Hot Stocks	BioCardia sees cash runway into 3Q23 » 08:19 03/29/23 03/29 08:19 03/29/23 08:19 BCDA BioCardia $2.19 / +0.1 (+4.78%) Net cash used in… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings On The Fly Events BCDA BioCardia $2.19 / +0.1 (+4.78%) 03/06/23 BioCardia present data from Phase III CardiAMP Cell Therapy Heart Failure trial 02/01/23 BioCardia and CellProthera extend partnership agreement 12/22/22 BioCardia CEO says coming year offers potential for catalysts 12/15/22 BioCardia announces $3.6M private placement of common stock BCDA BioCardia $2.19 / +0.1 (+4.78%) 11/17/22 Alliance Global Partners BioCardia price target lowered to $6 from $11.50 at Alliance Global Partners 11/11/22 Dawson James BioCardia downgraded to Neutral from Buy at Dawson James BCDA BioCardia $2.19 / +0.1 (+4.78%) 08:19 Today BioCardia reports 2022 EPS (67c) vs. (75c) last year 11/09/22 BioCardia reports Q3 EPS (17c), consensus (23c) BCDA BioCardia $2.19 / +0.1 (+4.78%) 12/08/22 Biotech Alert: Searches spiking for these stocks today 16:30 Today BioCardia - BCDA
Earnings	BioCardia reports 2022 EPS (67c) vs. (75c) last year » 08:19 03/29/23 03/29 08:19 03/29/23 08:19 BCDA BioCardia $2.19 / +0.1 (+4.78%) Reports 2022 revenue… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings On The Fly Events BCDA BioCardia $2.19 / +0.1 (+4.78%) 03/06/23 BioCardia present data from Phase III CardiAMP Cell Therapy Heart Failure trial 02/01/23 BioCardia and CellProthera extend partnership agreement 12/22/22 BioCardia CEO says coming year offers potential for catalysts 12/15/22 BioCardia announces $3.6M private placement of common stock BCDA BioCardia $2.19 / +0.1 (+4.78%) 11/17/22 Alliance Global Partners BioCardia price target lowered to $6 from $11.50 at Alliance Global Partners 11/11/22 Dawson James BioCardia downgraded to Neutral from Buy at Dawson James BCDA BioCardia $2.19 / +0.1 (+4.78%) 11/09/22 BioCardia reports Q3 EPS (17c), consensus (23c) BCDA BioCardia $2.19 / +0.1 (+4.78%) 12/08/22 Biotech Alert: Searches spiking for these stocks today 16:30 Today BioCardia - BCDA
Hot Stocks	Olink technology enables further development of South African research » 08:18 03/29/23 03/29 08:18 03/29/23 08:18 OLK Olink $19.83 / -1.8 (-8.32%) Olink announced that the… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Syndicate On The Fly OLK Olink $19.83 / -1.8 (-8.32%) 03/21/23 Olink announces Bruno Rossi joins the company as Chief Commercial Officer 03/06/23 Olink implementation of technology at NUS Medicine 02/28/23 Olink establishes agreement with RGC to scale proteomics efforts 11/03/22 Olink announces 1,000 peer-reviewed articles citing use of PEA technology OLK Olink $19.83 / -1.8 (-8.32%) 01/05/23 Scotiabank Olink initiated with an Outperform at Scotiabank 01/04/23 Scotiabank Olink initiated with an Outperform at Scotiabank 12/14/22 Canaccord Olink initiated with a Buy at Canaccord OLK Olink $19.83 / -1.8 (-8.32%) 02/21/23 Olink sees FY23 revenue $192M-$200M, consensus $193.48M 02/21/23 Olink reports Q4 EPS 5c, consensus 1c 01/09/23 Olink sees FY23 revenue $192M-$200M, consensus $199.3M 01/09/23 Olink narrows FY22 revenue view to $139.4M-$139.8M from $138M-142M 19 Jan OLK Olink $19.83 / -1.8 (-8.32%) 02/21/23 Fly Intel: Pre-market Movers 01/18/23 Fly Intel: After-Hours Movers
Hot Stocks	Verses, SimWell partner to enhance digital twin stimulations with KOSMOS » 08:17 03/29/23 03/29 08:17 03/29/23 08:17 VRSSF Verses Technologies / + VERSES Technologies… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News VRSSF Verses Technologies / + 03/22/23 Verses Technologies closes second tranche of convertible debenture financing 03/01/23 Verses closes $5M tranche, announces upsize of convertible debenture financing 02/27/23 Verses Technologies announces convertible debenture financing up to C$5M 02/23/23 Verses Technologies announces General Intelligent Agent, codenamed GIA

Hot Stocks	Crispr Therapeutics announces departure of board member » 08:16 03/29/23 03/29 08:16 03/29/23 08:16 CRSP Crispr Therapeutics $43.84 / -0.49 (-1.11%) CRISPR Therapeutics… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Events Options CRSP Crispr Therapeutics $43.84 / -0.49 (-1.11%) 03/27/23 Vertex Pharmaceuticals, Crispr Therapeutics enter CRISPR/Cas9 licensing pact 03/13/23 Crispr Therapeutics CFO Brendan Smith to depart, Raju Prasad to succeed 12/27/22 Cathie Wood's ARK Investment bought 10.8K shares of Crispr Therapeutics today 12/19/22 Crispr Therapeutics appoints Harding as SVP, Head of Business Development CRSP Crispr Therapeutics $43.84 / -0.49 (-1.11%) 03/21/23 Bernstein Crispr Therapeutics initiated with a Market Perform at Bernstein 03/18/23 Citi Crispr Therapeutics price target lowered to $55 from $63 at Citi 03/17/23 Bryan Garnier Crispr Therapeutics initiated with a Buy at Bryan Garnier 03/06/23 Baird Baird starts Crispr at Neutral with strong launch priced in CRSP Crispr Therapeutics $43.84 / -0.49 (-1.11%) 02/22/23 Crispr Therapeutics reports Q4 EPS ($1.41) vs. ($1.84) y/y 04/03/23 The Future of Oncology Virtual Symposium CRSP Crispr Therapeutics $43.84 / -0.49 (-1.11%) 02/21/23 Crispr Therapeutics options imply 4.4% move in share price post-earnings 02/14/23 Crispr Therapeutics options imply 4.9% move in share price post-earnings 01/05/23 Crispr Therapeutics call volume above normal and directionally bullish
Hot Stocks	G Medical Innovations enters into agreement with AdventHealth Central Florida » 08:15 03/29/23 03/29 08:15 03/29/23 08:15 GMVD G Medical Innovations $1.89 / -0.05 (-2.58%) G Medical Innovations… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News GMVD G Medical Innovations $1.89 / -0.05 (-2.58%) 03/27/23 G Medical Innovations, MiCare Path announce joint collaboration 02/13/23 G Medical Innovations receives patent from USPTO for vital sign sensors 01/30/23 G Medical Innovations granted patent by USPTO for vital signs sensors 12/05/22 G Medical Innovations receives two U.S. patents for monitoring products
Hot Stocks	Caribou initiates dose expansion portion of CB-010 ANTLER Phase 1 trial » 08:15 03/29/23 03/29 08:15 03/29/23 08:15 CRBU Caribou Biosciences $4.71 / +0.02 (+0.43%) Caribou Biosciences… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings CRBU Caribou Biosciences $4.71 / +0.02 (+0.43%) 08:12 Today Caribou Biosciences doses first patient in CaMMouflage Phase 1 trial of CB-011 12/12/22 Caribou Biosciences reports CB-010 ANTLER Phase 1 trial progress 12/12/22 Caribou Biosciences selects ROR1 as target for CB-020 11/29/22 Caribou Biosciences announces FDA granted RMAT, FTD to CB-010 CRBU Caribou Biosciences $4.71 / +0.02 (+0.43%) 03/18/23 BofA Caribou Biosciences price target lowered to $25 from $27 at BofA 03/14/23 H.C. Wainwright Caribou Biosciences price target lowered to $26 from $27 at H.C. Wainwright 03/10/23 Oppenheimer Caribou Biosciences price target lowered to $32 from $36 at Oppenheimer 11/23/22 Citi Caribou Biosciences price target lowered to $37 from $38 at Citi CRBU Caribou Biosciences $4.71 / +0.02 (+0.43%) 03/09/23 Caribou Biosciences reports Q4 EPS (44c), consensus (46c) 11/08/22 Caribou Biosciences reports Q3 revenue $3.3M, consensus $3.7M
Hot Stocks	First Solar announces facility in India awarded financial incentives » 08:13 03/29/23 03/29 08:13 03/29/23 08:13 FSLR First Solar $210.01 / +0.08 (+0.04%) First Solar announced… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Options FSLR First Solar $210.01 / +0.08 (+0.04%) 03/01/23 Origis Energy enters agreeent with First Solar for 2 GW of modules 02/28/23 First Solar announces Lightsource bp places multi-year order for 4 GW 01/12/23 First Solar completes sale of 141 MW Luz del Norte power plant to Toesca 12/19/22 First Solar to replace Fortune Brands in S&P 500 at open on 12/19 FSLR First Solar $210.01 / +0.08 (+0.04%) 03/23/23 Barclays First Solar price target raised to $230 from $162 at Barclays 03/15/23 Credit Suisse First Solar price target raised to $163 from $152 at Credit Suisse 03/14/23 Argus First Solar price target raised to $261 from $176 at Argus 03/09/23 Citi First Solar transferred with Neutral rating at Citi FSLR First Solar $210.01 / +0.08 (+0.04%) 02/28/23 First Solar sees FY23 EPS $7.00-$8.00, consensus $4.77 02/28/23 First Solar reports Q4 EPS (7c), consensus (15c) 02/28/23 Notable companies reporting after market close 10/27/22 First Solar reports Q3 EPS (46c), consensus (27c) FSLR First Solar $210.01 / +0.08 (+0.04%) 12/02/22 Chinese solar producers dodged U.S. tariffs, WSJ reports FSLR First Solar $210.01 / +0.08 (+0.04%) 03/06/23 What You Missed This Week in EVs and Clean Energy 03/03/23 What You Missed On Wall Street On Friday 03/03/23 What You Missed On Wall Street This Morning 02/28/23 Fly Intel: After-Hours Movers FSLR First Solar $210.01 / +0.08 (+0.04%) 03/08/23 Unusually active option classes on open March 8th 03/06/23 Early notable gainers among liquid option names on March 6th 03/03/23 Early notable gainers among liquid option names on March 3rd 03/01/23 Early notable gainers among liquid option names on March 1st
Hot Stocks	Caribou Biosciences doses first patient in CaMMouflage Phase 1 trial of CB-011 » 08:12 03/29/23 03/29 08:12 03/29/23 08:12 CRBU Caribou Biosciences $4.71 / +0.02 (+0.43%) Caribou Biosciences… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings CRBU Caribou Biosciences $4.71 / +0.02 (+0.43%) 12/12/22 Caribou Biosciences reports CB-010 ANTLER Phase 1 trial progress 12/12/22 Caribou Biosciences selects ROR1 as target for CB-020 11/29/22 Caribou Biosciences announces FDA granted RMAT, FTD to CB-010 11/21/22 Caribou Biosciences announces FDA clearance of IND application for CB-011 CRBU Caribou Biosciences $4.71 / +0.02 (+0.43%) 03/18/23 BofA Caribou Biosciences price target lowered to $25 from $27 at BofA 03/14/23 H.C. Wainwright Caribou Biosciences price target lowered to $26 from $27 at H.C. Wainwright 03/10/23 Oppenheimer Caribou Biosciences price target lowered to $32 from $36 at Oppenheimer 11/23/22 Citi Caribou Biosciences price target lowered to $37 from $38 at Citi CRBU Caribou Biosciences $4.71 / +0.02 (+0.43%) 03/09/23 Caribou Biosciences reports Q4 EPS (44c), consensus (46c) 11/08/22 Caribou Biosciences reports Q3 revenue $3.3M, consensus $3.7M
Recommendations	Viking Therapeutics price target raised to $25 from $15 at Maxim » 08:12 03/29/23 03/29 08:12 03/29/23 08:12 VKTX Viking Therapeutics $15.41 / +6.28 (+68.78%) Maxim raised the… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Options VKTX Viking Therapeutics $15.41 / +6.28 (+68.78%) 03/28/23 Viking Therapeutics initiates Phase 1 study of novel formulation of VK2735 03/28/23 Viking Therapeutics jumps 32% to $12.06 after Phase 1 VK2735 trial results 03/28/23 Viking Therapeutics announces results from Phase 1 trial of VK2735 01/09/23 Viking Therapeutics completes enrollment in Phase 2b VOYAGE study of VK2809 VKTX Viking Therapeutics $15.41 / +6.28 (+68.78%) 06:15 Today Raymond James Viking Therapeutics price target raised to $35 from $12 at Raymond James 03/28/23 BTIG Viking Therapeutics price target raised to $31 from $20 at BTIG 03/28/23 Oppenheimer Viking Therapeutics price target raised to $30 from $20 at Oppenheimer 03/28/23 Stifel Stifel reiterates Buy on Viking Therapeutics, raises price target to $25 VKTX Viking Therapeutics $15.41 / +6.28 (+68.78%) 02/08/23 Viking Therapeutics reports Q4 EPS (26c), consensus (23c) 10/26/22 Viking Therapeutics reports Q3 EPS (21c), consensus (23c) VKTX Viking Therapeutics $15.41 / +6.28 (+68.78%) 01/02/23 Viking sued Ascletis alleging stolen trade secrets, Reuters reports VKTX Viking Therapeutics $15.41 / +6.28 (+68.78%) 03/28/23 What You Missed On Wall Street On Tuesday 03/28/23 What You Missed On Wall Street This Morning 12/21/22 Biotech Alert: Searches spiking for these stocks today 12/19/22 Trial success is rocketing this NASH stock higher and sinking these peers VKTX Viking Therapeutics $15.41 / +6.28 (+68.78%) 03/21/23 Viking Therapeutics call volume above normal and directionally bullish 03/16/23 Viking Therapeutics call volume above normal and directionally bullish 03/08/23 Viking Therapeutics call volume above normal and directionally bullish 02/17/23 Viking Therapeutics call volume above normal and directionally bullish
Hot Stocks	Enphase Energy launches new IQ8 microinverters in France, the Netherlands » 08:12 03/29/23 03/29 08:12 03/29/23 08:12 ENPH Enphase Energy $193.50 / -2.28 (-1.16%) Enphase Energy announced… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Options ENPH Enphase Energy $193.50 / -2.28 (-1.16%) 03/20/23 Enphase Energy expands IQ8 microinverter deployments in Virginia 03/13/23 Enphase Energy expands IQ8 microinveter deployments in Utah 03/06/23 Enphase Energy expands IQ8 microinverter deployments in Illinois 02/26/23 Fly Intel: Top five weekend stock stories ENPH Enphase Energy $193.50 / -2.28 (-1.16%) 03/22/23 Susquehanna Enphase upgraded to Positive on recent pullback at Susquehanna 03/22/23 Susquehanna Enphase Energy upgraded to Positive from Neutral at Susquehanna 03/20/23 Raymond James Enphase Energy upgraded to Outperform from Market Perform at Raymond James 03/09/23 Citi Enphase Energy transferred with Buy rating at Citi ENPH Enphase Energy $193.50 / -2.28 (-1.16%) 02/07/23 Enphase Energy sees Q1 revenue $700M-$740M, consensus $690.46M 02/07/23 Enphase Energy reports Q4 EPS $1.51, consensus $1.24 02/07/23 Notable companies reporting after market close 10/25/22 Enphase Energy sees Q4 revenue $680M-$720M, consensus $660.21M ENPH Enphase Energy $193.50 / -2.28 (-1.16%) 02/25/23 Corning, Enphase among key U.S. Clean Energy players, Barron's says ENPH Enphase Energy $193.50 / -2.28 (-1.16%) 03/27/23 What You Missed This Week in EVs and Clean Energy 03/22/23 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 03/20/23 What You Missed On Wall Street On Monday 03/20/23 What You Missed On Wall Street This Morning ENPH Enphase Energy $193.50 / -2.28 (-1.16%) 03/23/23 Early notable gainers among liquid option names on March 23rd 03/20/23 Early notable gainers among liquid option names on March 20th 03/06/23 Early notable gainers among liquid option names on March 6th 02/27/23 Early notable gainers among liquid option names on February 27th
Hot Stocks	Akari announces Poland, U.K. approve new manufacturing process for nomacopan » 08:10 03/29/23 03/29 08:10 03/29/23 08:10 AKTX Akari Therapeutics / + Akari Therapeutics… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research AKTX Akari Therapeutics / + 02/21/23 Akari Therapeutics presents case study from Phase 3 Part A trial of nomacopan 02/15/23 Akari announces pre-clinical development progress toward IND for GA treatment 02/13/23 Akari Therapeutics announces acceleration of Phase 3 trial of nomacopan 11/10/22 Akari Therapeutics announces FDA granted RPDD to nomacopan AKTX Akari Therapeutics / + 12/05/22 H.C. Wainwright Akari Therapeutics initiated with a Buy at H.C. Wainwright 11/01/22 Alliance Global Partners Akari Therapeutics initiated with a Buy at Alliance Global Partners
Upgrade	Anhui Conch Cement upgraded to Neutral from Sell at Goldman Sachs » 08:10 03/29/23 03/29 08:10 03/29/23 08:10 AHCHY Anhui Conch Cement $17.45 / +0.26 (+1.51%) Goldman Sachs analyst… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Street Research AHCHY Anhui Conch Cement $17.45 / +0.26 (+1.51%) 11/15/22 HSBC Anhui Conch Cement upgraded to Buy from Hold at HSBC 08/28/22 Goldman Sachs Anhui Conch Cement downgraded to Sell from Neutral at Goldman Sachs
Hot Stocks	Kala Pharmaceuticals appoints Francis Mah as chief medical advisor » 08:10 03/29/23 03/29 08:10 03/29/23 08:10 KALA Kala Pharmaceuticals $15.59 / +0.59 (+3.93%) Kala Pharmaceuticals… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings On The Fly Events KALA Kala Pharmaceuticals $15.59 / +0.59 (+3.93%) 03/27/23 Kala announces safety update from Cohort 1 of CHASE Phase 2b trial 02/14/23 Kala recruiting for study of KPI-012 in participants with PCED 01/19/23 Kala Pharmaceuticals falls 10% to $15.90 after equity offering 12/30/22 Kala Pharmaceuticals trading resumes KALA Kala Pharmaceuticals $15.59 / +0.59 (+3.93%) 03/06/23 H.C. Wainwright Kala Pharmaceuticals price target raised to $20 from $12 at H.C. Wainwright 12/29/22 Wedbush IND acceptance sets up Kala for execution year in 2023, says Wedbush 11/09/22 Wedbush Kala Pharmaceuticals price target raised to $47 from $3 at Wedbush 05/24/22 H.C. Wainwright Kala Pharmaceuticals price target lowered to $4 from $5 at H.C. Wainwright KALA Kala Pharmaceuticals $15.59 / +0.59 (+3.93%) 03/03/23 Kala Pharmaceuticals reports Q4 EPS ($7.97) vs ($33.94) last year 11/08/22 Kala Pharmaceuticals reports Q3 EPS $19.25 vs ($21.41) last year KALA Kala Pharmaceuticals $15.59 / +0.59 (+3.93%) 01/19/23 Fly Intel: After-Hours Movers 12/30/22 Biotech Alert: Searches spiking for these stocks today 12/29/22 Biotech Alert: Searches spiking for these stocks today 12/28/22 Fly Intel: After-Hours Movers 04/24/23 Kala Pharmaceuticals, Inc.

Hot Stocks	NV5 awarded $11M essential infrastructure projects in California, New Mexico » 08:09 03/29/23 03/29 08:09 03/29/23 08:09 NVEE NV5 Global $100.90 / +0.02 (+0.02%) NV5 Global announced that… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings NVEE NV5 Global $100.90 / +0.02 (+0.02%) 03/13/23 NV5 Global announces $11M in engineering, planning awards 03/06/23 NV5 Global announces Axim Geospatial awarded $9M in national security contracts 03/02/23 NV5 Global acquires Gaudet Associates 02/23/23 NV5 Global announces acquisition of Axim Geospatial NVEE NV5 Global $100.90 / +0.02 (+0.02%) 02/24/23 Baird NV5 Global price target lowered to $130 from $150 at Baird 08/05/22 Lake Street NV5 Global price target raised to $175 from $136 at Lake Street NVEE NV5 Global $100.90 / +0.02 (+0.02%) 02/23/23 NV5 Global reports Q4 EPS $1.21 , consensus $1.57 11/03/22 NV5 Global reports Q3 adjusted EPS $1.50, consensus $1.45
Hot Stocks	DoubleDown announces results of 2023 Annual General Meeting » 08:09 03/29/23 03/29 08:09 03/29/23 08:09 DDI DoubleDown $8.09 / +0.08 (+1.00%) DoubleDown Interactive… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research DDI DoubleDown $8.09 / +0.08 (+1.00%) 01/11/23 DoubleDown to acquire i-Gaming company SuprNation for $35M 12/28/22 DoubleDown announces results of EGM held on December 28 DDI DoubleDown $8.09 / +0.08 (+1.00%) 09/15/22 Macquarie DoubleDown initiated with an Outperform at Macquarie 07/11/22 B. Riley Investors have overlooked DoubleDown, says B. Riley 06/28/22 B. Riley DoubleDown price target lowered to $20 from $30 at B. Riley
Initiation	Engie Brasil initiated with an Outperform at Scotiabank » 08:09 03/29/23 03/29 08:09 03/29/23 08:09 EGIEY Engie Brasil $8.00 / +0.34 (+4.44%) Scotiabank analyst Renato… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Street Research EGIEY Engie Brasil $8.00 / +0.34 (+4.44%) 03/07/23 UBS Engie Brasil upgraded to Buy from Neutral at UBS 01/10/23 JPMorgan Engie Brasil upgraded to Overweight from Neutral at JPMorgan 10/14/22 JPMorgan Engie Brasil upgraded to Neutral from Underweight at JPMorgan 08/08/22 JPMorgan Engie Brasil downgraded to Underweight from Neutral at JPMorgan
Recommendations	LuxUrban Hotels price target raised to $7 from $6 at Maxim » 08:08 03/29/23 03/29 08:08 03/29/23 08:08 LUXH LuxUrban Hotels $2.31 / -0.12 (-4.95%) Maxim raised the… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings LUXH LuxUrban Hotels $2.31 / -0.12 (-4.95%) 02/16/23 LuxUrban Hotels announces preferred U.S.hotel partnership with NusaTrip 02/08/23 LuxUrban in MLA deals for LA hotel O and 101 Bogart Street in NY, no terms 12/02/22 LuxUrban Hotels names Jimmie Chatmon COO 12/01/22 LuxUrban Hotels acquires Townhouse Hotel in South Beach, FL LUXH LuxUrban Hotels $2.31 / -0.12 (-4.95%) 12/12/22 Maxim LuxUrban Hotels initiated with a Buy at Maxim LUXH LuxUrban Hotels $2.31 / -0.12 (-4.95%) 01/18/23 LuxUrban Hotels affirms FY22 net rental revenue and EBITDA guidance
Hot Stocks	Harmony Biosciences reports accelerated timeline for Phase 3 hypersomnia study » 08:08 03/29/23 03/29 08:08 03/29/23 08:08 HRMY Harmony Biosciences $30.81 / -10.69 (-25.76%) Harmony Biosciences… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly HRMY Harmony Biosciences $30.81 / -10.69 (-25.76%) 03/28/23 Harmony Biosciences 'disagrees' with Scorpion Capital's 'assertions' 01/09/23 Novavax names John Jacobs as new CEO, succeeding Stanley Erck 01/06/23 Harmony Biosciences CEO John Jacobs stepping down 11/15/22 Harmony Biosciences director sells $9.12M in common stock HRMY Harmony Biosciences $30.81 / -10.69 (-25.76%) 03/28/23 Mizuho Harmony short report 'misleading,' 'perhaps even sensational,' says Mizuho 03/28/23 Raymond James Raymond James says buy Harmony on weakness after 'low quality' short report 02/22/23 Mizuho Harmony Biosciences price target lowered to $60 from $70 at Mizuho 01/04/23 Piper Sandler Harmony Biosciences price target raised to $70 from $62 at Piper Sandler HRMY Harmony Biosciences $30.81 / -10.69 (-25.76%) 02/21/23 Harmony Biosciences reports Q4 non-GAAP EPS $1.01, consensus 58c 11/01/22 Harmony Biosciences reports Q3 non-GAAP EPS 95c vs 41c last year HRMY Harmony Biosciences $30.81 / -10.69 (-25.76%) 03/28/23 Scorpion: Filing Citizen's Petition to request withdrawal of Harmony drug 03/28/23 Scorpion Capital issues investigative report on Harmony Biosciences HRMY Harmony Biosciences $30.81 / -10.69 (-25.76%) 03/28/23 What You Missed On Wall Street On Tuesday 03/28/23 What You Missed On Wall Street This Morning 03/28/23 Harmony plunges as Scorpion seeks FDA withdrawal of Wakix approval 10/14/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations

Events

Earnings calls, analyst events, roadshows and more

MINM
Today at 08:30

Minim - MINM Conference Calls
BLUE
Today at 08:30

Bluebird Bio - BLUE Conference Calls
BTMD
Today at 08:30

Biote - BTMD Conference Calls
GLYC
Today at 08:30

GlycoMimetics - GLYC Conference Calls
RDW
Today at 09:00

Redwire - RDW Conference Calls
BOSC
Today at 09:00

BOS Better Online Solutions - BOSC Conference Calls
IBEX
Today at 09:00

Ibex - IBEX Conference Calls
UNF
Today at 09:00

UniFirst - UNF Conference Calls
CLH
Today at 09:00

Clean Harbors Firm Sponsored Meetings

Virtual Meeting
PAYX
Today at 09:30

Paychex - PAYX Conference Calls

View All Events »

1 of

Syndicate

This week’s upcoming IPOs and secondary offerings

Priced
Not Priced

Mon	YGF X YGF YanGuFang IPO Managers: EF Hutton Priced at: $4.00 2M Shares ZJYL X ZJYL Jin Medical IPO Managers: Prime Number Priced at: $8.00 1M Shares
Tues	No deals
Wed	No deals
Thurs	No deals
Fri	No deals

Mon	No deals
Tues	No deals
Wed	BMEA X BMEA Biomea Fusion Secondary Managers: JPMorgan & Citi, Oppenheimer, Barclays $30.71 Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial
Thurs	SYT X SYT Syla Technologies IPO Managers: Boustead $8.00 1.875M Shares
Fri	No deals

View All Syndicate Announcements »

Celestica sees Q1 adjusted EPS 41c-47c, consensus 40c

OTHER BREAKING NEWS FROM THE FLY

Get Full Fly Access